Findings highlight the novel mechanism of
action and potential for therapeutic activity in highly
inflammatory autoimmune disease
SEATTLE, May 3, 2024
/PRNewswire/ -- Mozart Therapeutics, the leading developer of
CD8 Treg network modulators, today announce the release of new
pre-clinical data for their second program, a KIR x ICOS
bispecific antibody targeting CD8 regulatory T cells. The data will
be presented during the Immunology 2024 meeting, May 3–7 in
Chicago, Illinois.
Presentation highlights demonstrate KIR x ICOS
Modulator:
- Restores and potentiates CD8 Treg function through binding the
inhibitory receptor KIR and the costimulatory receptor ICOS, both
expressed on CD8 Treg
- Selectively activates CD8 Treg with dose-dependent increases in
both their prevalence and capacity to eliminate pathogenic CD4 T
cells
- Enhances ICOS signaling only in CD8 Treg and not other
ICOS-expressing immune cells
- Reduces proinflammatory cytokines and improves survival in a
highly inflammatory disease model
- Has acceptable tolerability in initial studies in humanized
mice
"Our preclinical data underscore the potential of our KIR x ICOS
CD8 Treg Modulator as a selective therapeutic approach for highly
inflammatory autoimmune diseases, including Crohn's disease and
ulcerative colitis. Findings show that the Modulator is selective
toward CD8 Treg, efficacious in models of disease, and has an
encouraging safety profile," said Dr. Kristine Swiderek, Chief Scientific Officer at
Mozart Therapeutics. "The data support further advancement of this
promising molecule."
Presentation Details:
Abstract:
|
#4471, Poster Board
#883
|
Session:
|
May 6, 2024, at
11:30 a.m. Central Daylight Time
|
Poster Title:
|
Pre-clinical
Pharmacology and Tolerability Characterization of a Novel
KIR x ICOS Targeting Bispecific CD8 Treg
Modulator"
|
The poster can be accessed from the Mozart Therapeutics
website following the May 6
presentation.
About KIR x ICOS Modulator
Inhibitory killer immunoglobulin-like receptors (KIR) are
autoimmune checkpoints expressed on CD8 regulatory T cells,
limiting their function of killing pathogenic CD4 T cells.
The inducible T cell costimulator (ICOS) is upregulated on
activated CD8 Treg and critical to CD8 Treg function.
KIR x ICOS is a bispecific antibody targeting CD8
Treg. The molecule aims to restore CD8 Treg function through
inhibition of KIR, while promoting ICOS-mediated CD8 Treg
activation, in chronic and highly inflammatory autoimmune
disease.
About Mozart Therapeutics
Mozart Therapeutics is focused on developing first-in-class
disease-modifying therapies for autoimmune and inflammatory
diseases, utilizing a novel approach to restoring immune system
homeostasis by targeting the CD8 Treg network. The company is
headquartered in Seattle, WA. For
more information, visit www.mozart-tx.com and follow the
company on LinkedIn @Mozart-tx.
Media
Contact:
Julie Rathbun
Rathbun
Communications
julie@rathbuncomm.com
206-769-9219
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mozart-therapeutics-to-present-pre-clinical-data-on-kir-x-icos-cd8-treg-modulator-at-immunology-2024-meeting-302135273.html
SOURCE Mozart Therapeutics